UK's Competition Watchdog Targets Four Firms Over Seven-Fold Prochlorperazine Price Hike

The UK CMA alleges that four companies were involved in a non-compete agreement that resulted in a 700% increase in the cost to the NHS of a generic medicine for nausea and dizziness.